An observational study in Contrast Media Allergy, sponsored by University Hospital, Montpellier. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by University Hospital, Montpellier · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hypersensitivity by University Hospital, Montpellier — 3 open to participants now, 4 under way, none of them phase 3. Hypersensitivity · University Hospital, Montpellier.
Among the 12 studies in Hypersensitivity by University Hospital, Montpellier, this one is one of 3 that started in 2026, is one of 8 observational ones, and was the 11th registered.
1,059 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.
Browse Hypersensitivity studies →3 of the 12 studies in Hypersensitivity by University Hospital, Montpellier are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 8–12
University Hospital, Montpellier · Sites in France
Ages 1+
By country, each count listing its studies:
Of the 101 Hypersensitivity studies recruiting now, 38 (38%) set no upper age limit and 51 (50%) stop at 75 or younger; 55 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 100 is below the median of 166 across 329 observational studies indexed under Hypersensitivity.
Median enrollment 388 across the 4 interventional studies, 181 across the 8 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
1 of the studies in Hypersensitivity by University Hospital, Montpellier that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997784University Hospital, MontpellierStudy of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Hypersensitivity by University Hospital, Montpellier, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study aims to evaluate the persistence of IgE-mediated allergy to contrast media (CM) after a second exposure in patients who tested positive at both the first and second evaluations for CM allergy. It also aims to analyze the risk factors associated with the persistence of IgE-mediated sensitization after the second allergological assessment.
Drug allergy is often overdiagnosed, as only about 25% of cases labeled as allergic are confirmed. IgE-mediated drug allergy, responsible for immediate reactions up to anaphylaxis, carries inherent risks and relies primarily on in vivo testing, supplemented by in vitro assays in selected cases. In vivo assessment includes skin tests (ST), which, when positive, detect drug-specific IgE bound to mast cells, and drug provocation tests (DPT), which involve controlled re-exposure to the suspected drug.
When IgE-mediated allergy is confirmed, drugs with positive ST are strictly contraindicated for life. Drugs with negative ST are generally considered safe, and tolerance is often verified through DPT performed in specialized settings using stepwise dose escalation up to near-therapeutic doses. In some cases, drugs are reintroduced directly in real-life conditions without prior DPT.
Contrast media (CM) can trigger systemic reactions even at very low doses. In such cases, in vitro testing should ideally precede DPT to minimize systemic exposure. However, its use is limited by the small number of commercially available drug allergens, the need for specialized expertise for techniques such as the basophil activation test, and variable sensitivity depending on the drug, which remains largely unknown for CM. Skin testing for CM allergy has a very high negative predictive value (>95%), indicating that most patients with negative ST tolerate subsequent CM exposure. As a result, many centers do not systematically perform DPT after negative ST.
Evidence suggests that IgE-mediated drug allergy, including CM allergy, may decline over time, with conversion from positive to negative ST occurring after several years. However, it is unclear whether this reflects a true loss of clinical allergy, as documented re-exposures are rare and mostly anecdotal. Clinical experience shows that allergy may either resolve or persist despite negative follow-up tests.
Finally, the severity of drug-induced allergic reactions may be increased in patients with mast cell activation syndrome or mastocytosis, conditions characterized by elevated mast cell burden or reactivity and often suspected in the presence of elevated baseline serum tryptase levels.
Drug Allergy and Hypersensitivity Database of the Allergy Exploration Unit, Montpellier University Hospital (CHU Montpellier).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Adult patients (≥18 years) with confirmed IgE-mediated allergy to contrast media products after a first exposure.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Skin testing using the prick method, involving gentle skin pricking at the site of allergen application, or intradermal testing (IDT) with 0.02-0.05 mL of allergenic solution will be performed in patients with a clinical history of hypersensitivity to contrast media. Baseline serum tryptase measured in blood samples will also be used as an indicator of hypersensitivity to contrast media, with values higher than 11 µg/L considered elevated.
Diagnostic Test: Skin testing · Other: Baseline serum tryptase measurement
Commercial contrast media will be used to perform skin prick testing or intradermal testing with 0.02-0.05 mL of allergenic solution. If not previously performed, a standard panel of prick tests with environmental allergens will be used to assess atopic status. Positive (histamine 10 mg/mL) and negative (saline) controls will be included. Skin testing will begin with prick tests, starting at the dilution that was positive during the initial evaluation. If negative, testing will proceed with intradermal injections using increasing concentrations until a positive response is observed. Once a positive result is obtained, skin testing for that contrast medium will be discontinued. A prick test will be considered positive if a wheal ≥3 mm with erythema and pruritus appears after 15 minutes. An intradermal test will be considered positive if a wheal ≥3 mm with erythema and pruritus appears after 20 minutes.
Seven milliliters of venous blood will be collected for baseline serum tryptase measurement.
Prevalence of IgE-mediated allergy to contrast media after the first exposure
A skin prick test is considered positive if, after 15 minutes, a wheal measuring at least 3 mm appears, associated with erythema and pruritus. An intradermal test is considered positive if, after 20 minutes, a wheal measuring at least 3 mm appears, associated with erythema and pruritus
Time frame: Inclusion
Risk factors of patients with IgE-mediated hypersensitivity to contrast media
The presence of risk factors will be determined by analyzing the association between data extracted from the Drug Allergy and Hypersensitivity Database (DAHD) (i.e., sociodemographic characteristics, initial reaction to contrast media, results of the first allergy tests, and the presence of other allergic factors) and the persistence of reactivity to contrast media in patients with serum tryptase levels higher than 11 µg/L.
Time frame: Inclusion
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Feb 2028, 24 months later.
Of 102 non-industry observational studies under Hypersensitivity, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 203. This study's planned 24 months is below that.
Counting every sponsor, half of 125 studies reached it within 41 months; a quarter within 19 and three quarters within 136.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →